LivaNova PLC (NASDAQ:LIVN) Shares Sold by Legal & General Group Plc

Legal & General Group Plc trimmed its holdings in LivaNova PLC (NASDAQ:LIVN) by 1.2% during the fourth quarter, HoldingsChannel.com reports. The firm owned 113,728 shares of the company’s stock after selling 1,343 shares during the period. Legal & General Group Plc’s holdings in LivaNova were worth $5,267,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in LIVN. Russell Investments Group Ltd. increased its stake in shares of LivaNova by 17.1% in the fourth quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company’s stock worth $70,000 after buying an additional 219 shares during the last quarter. Xponance Inc. increased its position in shares of LivaNova by 6.1% in the 4th quarter. Xponance Inc. now owns 7,762 shares of the company’s stock worth $359,000 after purchasing an additional 445 shares during the last quarter. Invesco Ltd. raised its stake in shares of LivaNova by 0.6% in the 4th quarter. Invesco Ltd. now owns 111,374 shares of the company’s stock valued at $5,158,000 after purchasing an additional 667 shares in the last quarter. Swiss National Bank lifted its position in shares of LivaNova by 0.7% during the fourth quarter. Swiss National Bank now owns 106,819 shares of the company’s stock worth $4,947,000 after purchasing an additional 700 shares during the last quarter. Finally, Central Pacific Bank Trust Division lifted its position in shares of LivaNova by 21.2% during the fourth quarter. Central Pacific Bank Trust Division now owns 4,117 shares of the company’s stock worth $191,000 after purchasing an additional 720 shares during the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

LivaNova Stock Performance

Shares of LIVN opened at $35.58 on Monday. The firm has a fifty day moving average of $40.08 and a 200-day moving average of $46.67. The company has a market cap of $1.93 billion, a price-to-earnings ratio of 84.71 and a beta of 0.90. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37. LivaNova PLC has a 1 year low of $32.48 and a 1 year high of $64.48.

Wall Street Analyst Weigh In

LIVN has been the topic of several research reports. Wolfe Research cut LivaNova from an “outperform” rating to a “peer perform” rating in a research note on Wednesday, February 26th. Stifel Nicolaus reduced their price objective on LivaNova from $72.00 to $60.00 and set a “buy” rating on the stock in a research note on Wednesday, February 26th. Needham & Company LLC reiterated a “buy” rating and set a $64.00 target price on shares of LivaNova in a research note on Monday, March 17th. StockNews.com upgraded shares of LivaNova from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, March 25th. Finally, Mizuho decreased their price target on shares of LivaNova from $70.00 to $60.00 and set an “outperform” rating for the company in a report on Wednesday, February 26th. Two investment analysts have rated the stock with a hold rating, five have given a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $61.17.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.